Begin marketing the drug

IIPM MANAGEMENT INSTITUTE

Today, the company has 250 employees working on all aspects of drug discovery, identification, synthesis, and testing. One compound, Yondelis, which is derived from a tunicate named Ecteinascidia turbinata, is close to receiving approval for treatment of soft-tissue sarcomas. Yondelis is also being studied for the treatment of ovarian, breast, and prostate cancer. Four other compounds are in earlier testing phases. And according to Cuevas, a handful more a re promising, though she says it’s too early to be specific.

“If we pass the European authorities and begin marketing the drug, this will be an important moment,” says Cuevas. “It’s important for the company, because it will be the first pharmacological drug that PharmaMar puts out on the market. It’s important for the marine-science community, because it will be the first marine cancer drug on the market. And in general, it will show that this isn’t a crazy idea, as people thought when Dr. Fernández-Sousa started. It will demonstrate that the sea can be an important source for new drugs.”

For Complete IIPM Article, Click on IIPM Article

Source : IIPM Editorial, 2007

An IIPM and Professor Arindam Chaudhuri (Renowned Management Guru and Economist) Initiative

For More IIPM Article, Visit Below....
http://iipm-top-mba-institute.spaces.live.com/
http://iipm-here-is-your-future.spaces.live.com/
http://iipm-campus-events.spaces.live.com/
http://iipm-institute.spaces.live.com/